利奈唑胺治疗耐多药结核病的现状及认识  

Current situation and perplexity of linezolid in the treatment of drug-resistant tuberculosis

作　　者：唐怡敏[1] 邓国防[1] 叶涛生[1] 刘映霞[2] 

机构地区：[1]南华大学深圳市第三人民医院肺科,518112 [2]南华大学深圳市第三人民医院感染科,518112

出　　处：《中国防痨杂志》2017年第6期659-663,共5页Chinese Journal of Antituberculosis

摘　　要：目前，耐多药结核病（MDR-TB）和泛耐药结核病（XDR-TB）仍是严重危害人类健康的全球公共卫生问题之一，但因治疗尚缺乏有效的药物，给临床治疗带来较大的困难。利奈唑胺（1inezolid，LZD）是一种人工合成的噁唑烷酮类抗生素，对结核分枝杆菌（MTB）有杀菌作用，其临床疗效已得到一系列临床研究证实。但在使用过程中，对该药的认识还存在一定的困惑。作者就LZD治疗耐多药结核病的现状、作用特点和使用过程中面临的耐药性、安全性、使用剂量等问题做一综述，旨在提高医务人员对LZD治疗耐多药结核病的认识。Multidrug-resistant tuberculosis （MDR-TB） and extensively drug-resistant TB are still a serious global public health problems. The treatment of drug-resistant TB is very difficult because of lack of effective drugs. Linezolid is a synthetic oxazolidinone antibacterial drugs and has bactericidal effect on Mycobacterium tuberculosis. Its clinical efficacy has been confirmed by a series of clinical studies. However, in the course of using linezolid, there is still some confusion. We reviewed treatment of drug-resistant tuberculosis using linezolid including the drug resistance, safety, dosage and so on, in order to elucidate the effect of linezolid in the treatment of MDR-TB.

关 键 词：结核 抗多种药物性 恶唑烷酮类 剂量效应关系 药物 药物流行病学 综述 

分 类 号：R52[医药卫生—内科学]